New research shows glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly lower stoma output, offering a promising option for managing high output stomas.

• Three studies found GLP-1 RAs led to up to a 50% reduction in stoma output.
• Patients showed improved nutritional status and decreased dependence on parenteral nutrition.

Mild gastrointestinal side effects, mainly nausea, were reported, with no serious adverse events.

• More rigorous trials are needed to confirm these findings and standardize treatment protocols.